The EXHALE 1B Study

• Research type

  Research Study

• Full title

  Assessment of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) as measured using a new device (Inflammacheck™) in patients with Interstitial Lung Disease, Lung Cancer and healthy volunteers. The EXHALE 1B study.

• IRAS ID

  236854

• Contact name

  Anoop Chauhan

• Contact email

  anoop.chauhan@porthosp.nhs.uk

• Sponsor organisation

  Portsmouth Hospitals NHS Trust

• Duration of Study in the UK

  1 years, 8 months, 30 days

• Research summary

  Lung Fibrosis is difficult to diagnose and the numbers of people affected are increasing year on year. Lung Cancer is the leading cause of cancer death worldwide, with a very poor chance of survival if it is diagnosed late, as is often to case in the UK. These groups of patients suffer significantly from breathlessness and lung infections that can go undiagnosed or untreated.
  The personal cost of undiagnosed lung fibrosis and lung cance is huge, and it is also costly to the NHS. There is a great need for new tests to diagnose these conditions earlier and more effectively. A feature of fibrosis and cancer is inflammation which worsens as the disease progresses. Current ways of assessing airway inflammation are invasive and can cause the patient discomfort and harm. They also take time to provide a result to the medical team and to patients. If we can detect inflammation, in an easy, safe and quick way, we could potentially diagnose these lung diseases earlier allowing patients to recieve more prompt and appropiate care

  Inflammacheck is a new test which identifies a chemical in exhlaed breath. This chemical can give information about a patient's lungs. To do the test, patients will simply breathe into a small hand-held device at their normal rate of breathing for 1 minute. The device then gives an immediate result to the patient and their medical team.
  'Inflammacheck' now needs to be tested to see if the device can help in the diagnosis of lung fibrosis and Lung Cancer.
  We will recruit 75 people to the EXHALE 1B study, including 25 people with lung fibrosis, 25 people with Lung Cancer and 25 people with no known lung disease (our 'healthy controls').

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  18/SC/0157

• Date of REC Opinion

  1 May 2018

• REC opinion

  Favourable Opinion